Recursion Pharmaceuticals, Inc. (RXRX) Revenue Growth
Recursion Pharmaceuticals, Inc. (RXRX) year-over-year revenue growth rate history. Analyze revenue growth in Excel with MarketXLS.
Revenue Growth Data
| Period | YoY Revenue Growth |
|---|---|
| 2022-12-31 | 291.46% |
| 2023-12-31 | 11.88% |
| 2024-12-31 | 32.00% |
| 2025-12-31 | 26.92% |
How RXRX compares with sector peers
| Symbol | Company | Revenue growth (latest fiscal year) |
|---|---|---|
| AKBA | Akebia Therapeutics Inc. | 47.46% |
| RFL | Rafael Holdings Inc. Class B | 43.96% |
| IONS | Ionis Pharmaceuticals Inc. | 33.83% |
| NTLA | Intellia Therapeutics Inc. | 16.92% |
| BNTC | Benitec Biopharma Inc. | 2.74% |
These are five companies in the same sector as RXRX with a comparable annual revenue growth. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Recursion Pharmaceuticals, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Revenue_Growth("RXRX", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | RXRX | $3.63 | +5.52% | 28.99M |
| 3 | ||||
| 4 | ||||
| 5 |